生物制剂联合传统医药治疗中重度特应性皮炎的临床观察

目的 观察度普利尤单抗联合复方甘草酸苷片治疗中重度特应性皮炎的临床疗效及安全性。方法 将29例成人中重度特应性皮炎患者随机分为观察组14例和对照组15例,观察组给予度普利尤单抗联合复方甘草酸苷片治疗,对照组单用度普利尤单抗治疗,比较两组患者治疗后的临床疗效及不良反应情况。结果 治疗后第16周,观察组与对照组的平均EASI值变化百分比差异具有统计学意义(P＜0.05),表明随着疗程的延长,观察组的疗效优于对照组。两组均有2例患者发生结膜炎。结论 度普利尤单抗联合复方甘草酸苷片治疗中重度特应性皮炎较单用度普利尤单抗疗效更佳,且安全性好。

Clinical observation of biological agents combined with traditional medicine in the treatment of moderate and severe atopic dermatitis

Objective: To observe the clinical efficacy and safety of dupilumab combined with compound glycyrrhizin tablets in the treatment of moderate and severe atopic dermatitis. Methods: 29 adult patients with moderate to severe atopic dermatitis were randomly divided into 14 cases in the observation group and 15 cases in the control group. The observation group was treated with dupilumab combined with compound glycyrrhizin tablets, and the control group was treated with dupilumab alone. The clinical efficacy and adverse reactions of the two groups were compared. Results: at the 16th week after treatment, the mean of the percentage of decline in EASI score between the observation group and the control group was statistically significant (P<0.05), indicating that with the extension of the course of treatment, the curative effect of the observation group was better than that of the control group. Conjunctivitis occurred in 2 patients in both groups. Conclusion: dupilumab combined with compound glycyrrhizin tablets is more effective in the treatment of moderate and severe atopic dermatitis than dupilumab alone, and both are equally safe.